Indications for: EVKEEZA

Adjunct to other LDL-C lowering therapies for the treatment of patients with homozygous familial hypercholesterolemia (HoFH).

Limitations of Use:

Safety and efficacy have not been established for other causes of hypercholesterolemia, including heterozygous familial hypercholesterolemia (HeFH). Effects on cardiovascular morbidity and mortality have not been determined.

Adult Dosage:

Give by IV infusion over 60mins. ≥12yrs: 15mg/kg once monthly (every 4 weeks).

Children Dosage:

<12yrs: not established.

EVKEEZA Warnings/Precautions:

Discontinue if serious hypersensitivity reactions occur; monitor and treat appropriately. Assess LDL-C when clinically appropriate; effects may be measured as early as 2 weeks after initiation. Embryo-fetal toxicity. Advise females of reproductive potential to use effective contraception during and for at least 5 months after the last dose. Pregnancy: exclude status prior to initiation. Nursing mothers.

EVKEEZA Classification:

Angiopoietin-like 3 (ANGPTL3) inhibitor.

Adverse Reactions:

Nasopharyngitis, influenza-like illness, dizziness, rhinorrhea, nausea; hypersensitivity reactions.

Generic Drug Availability:


How Supplied:

Single-dose vial (2.3mL, 8mL)—1